Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia

University of Arkansas at Little Rock, Little Rock, Arkansas, United States
Cancer (Impact Factor: 4.89). 07/2005; 104(1):199-204. DOI: 10.1002/cncr.21142
Source: PubMed


Invasive fungal infections (IFI) in immunocompromised patients are associated with significant morbidity and mortality, despite appropriate antifungal treatment and recovery from neutropenia. The outcome of these infections depends significantly on the overall state of immunosuppression, including mainly the phagocytic system (neutrophils and macrophages). Interferon-gamma (IFN-gamma), granulocyte-colony--stimulating factor (G-CSF) and granulocyte-macrophage-colony--stimulating factor (GM-CSF) are cytokines that enhance the activity of neutrophils and macrophages.
The authors reported 4 patients with leukemia and refractory invasive candidiasis or trichosporonosis despite 1-13 months of appropriate antifungal treatment.
Cytokines were administered for 1.5-5 months without significant toxicity. For each patient, initiation of interferon-gamma plus a colony-stimulating factor resulted in a clinical response. The contribution of cytokines to control the fungal infection in these 4 patients was suggested by the strong inflammatory reaction observed in the 2 patients who had an immediate response (within 7 days of initiation of cytokine therapy) and by the good outcome in the 2 other patients in whom antifungal agents were discontinued at the start of cytokine therapy.
These data suggested a potential role for immunomodulation in patients with leukemia with refractory invasive fungal infections.

Download full-text


Available from: Ka Wah Chan, Oct 19, 2014
13 Reads
  • Source
    • "As such, it has been implicated as a treatment option in (invasive) fungal infections [20,21]. Moreover, limited evidence suggests that recombinant IFN-γ (rIFN-γ) has a beneficial effect on the outcome of fungal infections in patients with chronic granulomatous disease (CGD) [22], HIV [23-25], leukemia [26,27], and in patients receiving organ transplants [28]. However, it has not been investigated whether rIFN-γ actually enhances the immune response in these patients to explain these beneficial clinical effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections are very severe infections associated with high mortality rates, despite the availability of new classes of antifungal agents. Based on pathophysiological mechanisms and limited pre-clinical and clinical data, adjunctive immune-stimulatory therapy with interferon-gamma (IFN-gamma) may represent a promising candidate to improve outcome of invasive fungal infections by enhancing host defence mechanisms. In this open-label, prospective case series, we describe eight patients with invasive Candida and/or Aspergillus infections who were treated with recombinant IFN-gamma (rIFN-gamma, 100 mug s.c., thrice a week) for 2 weeks in addition to standard antifungal therapy. Recombinant IFN-gamma treatment in patients with invasive Candida and/or Aspergillus infections partially restored immune function, as characterized by an increased HLA-DR expression in those patients with a baseline expression below 50%, and an enhanced capacity of leukocytes from treated patients to produce proinflammatory cytokines involved in antifungal defence. The present study provides evidence that adjunctive immunotherapy with IFN-gamma can restore immune function in fungal sepsis patients, warranting future clinical studies to assess its potential clinical benefit.Trial registration: - NCT01270490.
    BMC Infectious Diseases 03/2014; 14(1):166. DOI:10.1186/1471-2334-14-166 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with hematologic malignancies and hematopoietic stem cell transplant recipients have a broad range of immune deficits that predispose to common and opportunistic infectious diseases. Infectious complications are a major cause of morbidity and mortality in these patients. Effective immune augmentation strategies used as prophylaxis and as adjunctive therapy represent an important unmet need. We discuss several immune-based strategies tailored to specific patient populations. These include strategies to augment neutrophil number, enhance function of neutrophils and macrophages, passive antibody therapy, and augmentation of cellular immunity. We evaluate immune-based therapies that are currently available and the evidence supporting their use. There is a large “pipeline” of novel and promising immunotherapies that are at preclinical and early stages of clinical development. These include augmentation of innate and antigen-specific immunity by stimulating pathogen recognition pathways, adoptive transfer of cellular immunity, and vaccine development. We review these more cutting-edge approaches, with an emphasis on opportunistic fungal and viral infections. We discuss gaps in knowledge and challenges in bringing promising immune-based therapies to clinical trials.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Supportive care issues play a very prominent role in the management of malignant disease. In this context, “supportive care” includes the prevention and treatment of both the complications of anti-neoplastic therapy and of the cancer itself. It is recognized that many of the increasingly effective intensive management strategies now used in oncologic practice could not be employed in the absence of a thorough understanding of these processes, and the development of helpful therapeutic approaches. In this chapter a number of supportive care topics, recently highlighted in the published peer-reviewed literature, are discussed. These include: (a) factors which predict for the development of various types of infectious events (bacterial, viral, fungal) in specific malignancies; (b) the clinical utility of oral versus intravenous antibiotics; (c) the benefits of prophylactic antibiotic therapy (d) outpatient management of neutropenic fever; (e) strategies to optimally manage bacterial, viral and fungal infections in cancer patients; (f) complications associated with the use of indwelling intravenous catheter systems in the oncology patient population and methods to both manage and prevent such events; (g) new developments in anti-emetic therapy; and (h) and a novel strategy to prevent treatment-associated mucositis.
    Cancer chemotherapy and biological response modifiers 02/2005; 22(2):677-86. DOI:10.1016/j.uct.2006.04.009
Show more